Rheostat Therapeutics Announces $23 Million Series A Financing; To Develop Potential Treatments for Neurodegenerative Diseases
Astellas Pharma : buys Potenza Therapeutics for up to $405m
The 2019 30-under-30 getting personal to fix the system
Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
Affinivax, Inc. announces initiation of Phase 1/2 clinical study of ASP3772, its novel pneumococcal MAPS vaccine, in collaboration with Astellas
Torque and Thermo Fisher Scientific Announce Collaboration to Build State-of-the-Art Facility to Manufacture Torque’s Deep-Primed T Cell Immunotherapies
Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings
Axial Biotherapeutics nets $25M for clinical gut-brain axis studies into autism and Parkinson’s
EnClear Therapies Announces Seed Funding and Senior R&D Appointment
LabCentral 2018 Impact Report: Resident Companies Raised the Equivalent of 40% of Early Life Sciences VC Funding in Massachusetts and 6% of U.S. Life Sciences IPOs
